Base de dados : MEDLINE
Pesquisa : D27.505.954.411.793.610 [Categoria DeCS]
Referências encontradas : 1541 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 155 ir para página                         

  1 / 1541 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28631690
[Au] Autor:Nosulya EV
[Ad] Endereço:Department of Otorhinolaryngology, Russian Medical Academy of Continuous Post-Graduate Education, Moscow, Russia, 125367.
[Ti] Título:[Medically-induced rhinitis].
[Ti] Título:Medikamentoznyi rinit..
[So] Source:Vestn Otorinolaringol;82(3):84-90, 2017.
[Is] ISSN:0042-4668
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:This paper summarizes the currently accepted concepts of the pathogenetic mechanisms underlying the morphological and functional changes in intranasal mucosa of the patients having a long history of the application of the long-acting topical vasoconstrictor agents. The author presents the data illustrating the effectiveness of various methods for the pharmacotherapeutic treatment of medically-induced rhinitis.
[Mh] Termos MeSH primário: Descongestionantes Nasais
Rinite
[Mh] Termos MeSH secundário: Administração Intranasal
Gerenciamento Clínico
Seres Humanos
Descongestionantes Nasais/administração & dosagem
Descongestionantes Nasais/efeitos adversos
Mucosa Nasal/patologia
Mucosa Nasal/fisiopatologia
Rinite/induzido quimicamente
Rinite/diagnóstico
Rinite/fisiopatologia
Rinite/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Nasal Decongestants)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.17116/otorino201782384-90


  2 / 1541 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28602009
[Au] Autor:Snidvongs K; Thanaviratananich S
[Ad] Endereço:Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. drkornkiat@yahoo.com.
[Ti] Título:Update on Intranasal Medications in Rhinosinusitis.
[So] Source:Curr Allergy Asthma Rep;17(7):47, 2017 Jul.
[Is] ISSN:1534-6315
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This review describes beneficial effects and adverse events of various intranasal medications in treating rhinosinusitis. Application of intranasal steroids has been described in treating all subtypes of adult rhinosinusitis, but reports are limited in pediatrics and mostly in acute pediatric subgroups resulted in benefits While saline irrigation is effective for patients with chronic rhinosinusitis without polyps and in pediatric acute rhinosinusitis, there is no evidence yet for saline drips and sprays. Application of intranasal antifungals and nasal irrigation with surfactant brings more harm than benefits. There is no evidence supporting the use of intranasal antibiotics. We also review influence of devices, methods, and patient head position on nasal and paranasal sinus drug delivery.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Antifúngicos/administração & dosagem
Rinite/tratamento farmacológico
Sinusite/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intranasal
Animais
Antagonistas dos Receptores Histamínicos/administração & dosagem
Seres Humanos
Descongestionantes Nasais/administração & dosagem
Lavagem Nasal
Pólipos Nasais/tratamento farmacológico
Cloreto de Sódio/administração & dosagem
Esteroides/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antifungal Agents); 0 (Histamine Antagonists); 0 (Nasal Decongestants); 0 (Steroids); 451W47IQ8X (Sodium Chloride)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170612
[St] Status:MEDLINE
[do] DOI:10.1007/s11882-017-0720-3


  3 / 1541 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28574526
[Au] Autor:Hollander-Rodriguez JC; Montjoy HL; Smedra B; Prouty JP
[Ad] Endereço:Cascades East Family Medicine Residency, Oregon Health & Science University, Portland, OR, USA.
[Ti] Título:Clinical Inquiry: Do oral decongestants have a clinically significant effect on BP in patients with hypertension?
[So] Source:J Fam Pract;66(6):E1-E2, 2017 Jun.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:It is unclear. Pseudoephedrine causes an average increase of 1.2 mm Hg in systolic blood pressure (BP) in patients with controlled hypertension. However, the studies are not adequately powered to provide evidence about whether this rise in systolic BP is linked to patient-oriented outcomes (strength of recommendation: C, multiple randomized controlled trials supporting disease-oriented evidence). Significant variations in BP are defined differently among studies. In addition, we do not have data on chronic use of oral decongestants; the longest time on medication in these trials was 4 weeks.
[Mh] Termos MeSH primário: Pressão Sanguínea/efeitos dos fármacos
Hipertensão/fisiopatologia
Descongestionantes Nasais/uso terapêutico
Pseudoefedrina/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
Descongestionantes Nasais/efeitos adversos
Pseudoefedrina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nasal Decongestants); 7CUC9DDI9F (Pseudoephedrine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170603
[St] Status:MEDLINE


  4 / 1541 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28532204
[Au] Autor:Carr WW; Yawn BP
[Ad] Endereço:a Physician, Allergy & Asthma Associates of Southern California, A Medical Group , Southern California Research , Mission Viejo , CA , USA.
[Ti] Título:Management of allergic rhinitis in the era of effective over-the-counter treatments.
[So] Source:Postgrad Med;129(6):572-580, 2017 Aug.
[Is] ISSN:1941-9260
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Allergic rhinitis (AR) may be regarded as a trivial issue unworthy of the doctor's time, and with the availability of many different over-the-counter (OTC) treatments, up to two thirds of patients self-manage AR before seeking medical care. Yet, AR can have a significant impact on health-related quality of life and is associated with a greater detriment to work productivity than other chronic diseases such as diabetes and hypertension. For many patients, the impact on quality of life is greater than suggested by reported symptoms and should also be a focus of treatment. Although many patients can effectively manage AR symptoms independently, a significant percentage will need direction from a physician to obtain optimal results. The availability of several different classes of treatment - including decongestants, sedating and non-sedating antihistamines, and more recently intranasal corticosteroids (INS) - has increased the complexity of self-management, leaving patients confused about the best approach to treatment. Treatment guidelines universally classify INS as the most effective medical agents available for use in the OTC and primary care settings. Many patients are unaware that INS are available OTC and that they are more effective than other therapies. Patients may have negative perceptions about the safety of INS and may have experienced unpleasant taste, scent, and feel with nasal sprays. Unless a patient volunteers the information, healthcare professionals (HCPs) may be unaware that the patient has significant AR and is using one or more OTC AR therapies. To address this gap in communication, HCPs must be proactive in identifying, assessing, and advising patients with AR, including best strategies to assess allergen trigger symptoms, which treatments are appropriate, and when and how to use them. Proper use of delivery devices is especially important. This article reviews the primary care management of AR in the context of the availability of effective OTC medicines.
[Mh] Termos MeSH primário: Medicamentos sem Prescrição/uso terapêutico
Rinite Alérgica/tratamento farmacológico
Autocuidado
[Mh] Termos MeSH secundário: Administração Intranasal
Administração Oral
Corticosteroides/administração & dosagem
Corticosteroides/uso terapêutico
Antagonistas dos Receptores Histamínicos/administração & dosagem
Antagonistas dos Receptores Histamínicos/uso terapêutico
Seres Humanos
Imunoterapia
Antagonistas de Leucotrienos/administração & dosagem
Antagonistas de Leucotrienos/uso terapêutico
Descongestionantes Nasais/administração & dosagem
Descongestionantes Nasais/uso terapêutico
Medicamentos sem Prescrição/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Histamine Antagonists); 0 (Leukotriene Antagonists); 0 (Nasal Decongestants); 0 (Nonprescription Drugs)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170524
[St] Status:MEDLINE
[do] DOI:10.1080/00325481.2017.1333384


  5 / 1541 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28326908
[Au] Autor:Brunton S; Nelson HS; Bernstein DI; Lawton S; Lu S; Nolte H
[Ad] Endereço:a Primary Care Respiratory Group , Lake View Terrace , CA , USA.
[Ti] Título:Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma.
[So] Source:Postgrad Med;129(6):581-589, 2017 Aug.
[Is] ISSN:1941-9260
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Allergic rhinitis (AR) with or without conjunctivitis (AR/C) is associated with a significant health and economic burden, and is often accompanied by asthma. Pharmacotherapies are the mainstay treatment options for AR and asthma, but guidelines also recommend allergy immunotherapy (AIT). Unlike pharmacotherapies, AIT has the ability to modify the underlying immunologic mechanisms of AR and asthma with the potential for long-term benefits after treatment is discontinued. Immunotherapy may also prevent progression of AR/C to asthma. Sublingual immunotherapy (SLIT)-tablets are a self-administered alternative to subcutaneous immunotherapy that provide the benefits of AIT without the cost and inconvenience of frequent office visits or the discomfort of injections. SLIT-tablets are also an option that can be utilized by primary care clinicians. Pharmacotherapies are generally effective in mild disease although a number of patients remain uncontrolled. SLIT-tablets have proven efficacy for AR in adults, children, and poly-sensitized allergic patients. Indirect comparisons indicate that SLIT-tablets have superior or comparable efficacy compared with traditional pharmacotherapies for seasonal AR, and superior efficacy for perennial AR. House dust mite (HDM) SLIT-tablets have also demonstrated clinically relevant benefits for asthma, with significant observed reductions in daily inhaled corticosteroid use, risk of asthma exacerbations, and asthma symptoms. SLIT-tablets are well tolerated, with minimal risk of systemic allergic reactions. The most common treatment-related adverse events are oral site reactions such as oral pruritus and throat irritation. Based on the favorable efficacy and safety profile, as well as the convenience of at-home oral administration and disease-modifying effects, SLIT-tablets should be considered as an alternative or add-on treatment to pharmacotherapy for AR/C, and as an add-on treatment for HDM allergic asthma.
[Mh] Termos MeSH primário: Asma/tratamento farmacológico
Asma/imunologia
Rinite Alérgica/tratamento farmacológico
Rinite Alérgica/imunologia
Imunoterapia Sublingual
[Mh] Termos MeSH secundário: Administração Intranasal
Administração Oral
Corticosteroides/administração & dosagem
Corticosteroides/uso terapêutico
Agonistas Adrenérgicos beta/administração & dosagem
Agonistas Adrenérgicos beta/uso terapêutico
Antagonistas dos Receptores Histamínicos/administração & dosagem
Antagonistas dos Receptores Histamínicos/uso terapêutico
Seres Humanos
Antagonistas de Leucotrienos/administração & dosagem
Antagonistas de Leucotrienos/uso terapêutico
Descongestionantes Nasais/administração & dosagem
Descongestionantes Nasais/uso terapêutico
Comprimidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Adrenergic beta-Agonists); 0 (Histamine Antagonists); 0 (Leukotriene Antagonists); 0 (Nasal Decongestants); 0 (Tablets)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE
[do] DOI:10.1080/00325481.2017.1308208


  6 / 1541 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28249059
[Au] Autor:Leventhal WD
[Ad] Endereço:Summerville, SC, USA.
[Ti] Título:An overlooked Rx for nasal obstruction relief.
[So] Source:J Fam Pract;66(3):135, 2017 Mar.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We frequently recommend ipratropium nasal spray in our office, as it is an effective, non-addictive nasal decongestant.
[Mh] Termos MeSH primário: Ipratrópio/administração & dosagem
Obstrução Nasal/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Descongestionantes Nasais/administração & dosagem
Sprays Nasais
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Nasal Decongestants); 0 (Nasal Sprays); GR88G0I6UL (Ipratropium)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE


  7 / 1541 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28122105
[Au] Autor:Bahtouee M; Monavarsadegh G; Ahmadipour M; Motieilangroodi M; Motamed N; Saberifard J; Eghbali S; Adibi H; Maneshi H; Malekizadeh H
[Ad] Endereço:Department of Internal Medicine, Persian Gulf Martyr's Hospital, Azadi Square, Bushehr, Bushehr Province, Iran 7517933755. bahtoueem@bpums.ac.ir.
[Ti] Título:Acetylcysteine in the treatment of subacute sinusitis: A double-blind placebo-controlled clinical trial.
[So] Source:Ear Nose Throat J;96(1):E7-E11, 2017 Jan.
[Is] ISSN:1942-7522
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sinusitis is a common disease with harmful effects on the health and finances of patients and the economy of the community. It is easily treated in most of its acute stages but is associated with some management difficulties as it goes toward chronicity. Therefore, we tried to improve the treatment of subacute sinusitis by using acetylcysteine, which is a safe mucolytic and antioxidant agent. Thirty-nine adult patients with subacute sinusitis proved by computed tomography (CT) were enrolled in a double-blind, placebo-controlled trial. They received oral amoxicillin-clavulanic acid and normal saline nasal drops for 10 days and oral pseudoephedrine for 7 days. In addition, the patients received acetylcysteine (600 mg orally, once daily) in the intervention group or placebo in the control group for 10 days. A paranasal CT scan was taken at baseline and 30 days after patients finished the treatment and was evaluated quantitatively by Lund-Mackay (LM) score. Symptoms and some aspects of quality of life also were assessed at baseline and 14 days after initiation and 30 days after termination of the treatment via the Sino-Nasal Outcome Test questionnaire. The groups showed no significant difference in LM score after treatment. A positive correlation was observed between the LM and SNOT-20 scores. We concluded that adding oral acetylcysteine to amoxicillin-clavulanic acid, pseudoephedrine, and intranasal normal saline has no benefit for the treatment of subacute sinusitis.
[Mh] Termos MeSH primário: Acetilcisteína/uso terapêutico
Depuradores de Radicais Livres/uso terapêutico
Sinusite/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico
Antibacterianos/uso terapêutico
Doença Crônica
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Descongestionantes Nasais/uso terapêutico
Seios Paranasais/diagnóstico por imagem
Pseudoefedrina/uso terapêutico
Sinusite/diagnóstico por imagem
Cloreto de Sódio/uso terapêutico
Inquéritos e Questionários
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Free Radical Scavengers); 0 (Nasal Decongestants); 451W47IQ8X (Sodium Chloride); 74469-00-4 (Amoxicillin-Potassium Clavulanate Combination); 7CUC9DDI9F (Pseudoephedrine); WYQ7N0BPYC (Acetylcysteine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170614
[Lr] Data última revisão:
170614
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170126
[St] Status:MEDLINE


  8 / 1541 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28061917
[Au] Autor:Boel NM; Klokker M
[Ti] Título:Upper Respiratory Infections and Barotrauma Among Commercial Pilots.
[So] Source:Aerosp Med Hum Perform;88(1):17-22, 2017 Jan 01.
[Is] ISSN:2375-6314
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Health incapacitation is a serious threat to flight safety. Therefore, a study conducted 10 yr ago examined the incidents of ear-nose-throat (ENT) barotrauma and upper respiratory infection (URI) among commercial pilots and found that a large number continued to carry out their duties despite the risk of incapacitation. Now, 10 yr later, this new study examines if the attention to URIs has improved. METHOD: This study was conducted at the Danish Aeromedical Centre over the course of 1 yr with 463 valid respondents to a questionnaire on URIs and ENT barotrauma. These respondents were compared to 940 respondents answering the same questionnaire 10 yr prior in the same setting. RESULTS: This study shows a significant increase in the number of pilots flying despite signs of an URI from 42.8 to 50.1% and in the number of pilots using decongestant medicine from 43.3 to 59.5%. The proportion of pilots experiencing one or more ENT barotraumas has also increased from 37.4 to 55.5% for barotitis media and from 19.5 to 27.9% for barosinusitis. CONCLUSION: Half of all pilots in this study fly despite signs of an URI. This is a significant increase and shows that after 10 yr an URI is still not considered a valid reason for reporting in sick despite international aeromedical recommendation. Based on these findings, the study recommends that awareness of the risk of flying with an URI be increased.Boel NM, Klokker M. Upper respiratory infections and barotrauma among commercial pilots. Aerosp Med Hum Perform. 2017; 88(1):17-22.
[Mh] Termos MeSH primário: Barotrauma/epidemiologia
Descongestionantes Nasais/uso terapêutico
Traumatismos Ocupacionais/epidemiologia
Otite Média/epidemiologia
Pilotos
Infecções Respiratórias/epidemiologia
Sinusite/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Medicina Aeroespacial
Aviação
Feminino
Seres Humanos
Incidência
Masculino
Meia-Idade
Saúde do Trabalhador
Infecções Respiratórias/tratamento farmacológico
Fatores de Risco
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nasal Decongestants)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170221
[Lr] Data última revisão:
170221
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:170108
[St] Status:MEDLINE
[do] DOI:10.3357/AMHP.4511.2017


  9 / 1541 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27992707
[Au] Autor:Maina M; Akech S; Mwaniki P; Gachau S; Ogero M; Julius T; Ayieko P; Irimu G; English M
[Ad] Endereço:KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
[Ti] Título:Inappropriate prescription of cough remedies among children hospitalised with respiratory illness over the period 2002-2015 in Kenya.
[So] Source:Trop Med Int Health;22(3):363-369, 2017 Mar.
[Is] ISSN:1365-3156
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To examine trends in prescription of cough medicines over the period 2002-2015 in children aged 1 month to 12 years admitted to Kenyan hospitals with cough, difficulty breathing or diagnosed with a respiratory tract infection. METHODS: We reviewed hospitalisation records of children included in four studies providing cross-sectional prevalence estimates from government hospitals for six time periods between 2002 and 2015. Children with an atopic illness were excluded. Amongst eligible children, we determined the proportion prescribed any adjuvant medication for cough. Active ingredients in these medicines were often multiple and were classified into five categories: antihistamines, antitussives, mucolytics/expectorants, decongestants and bronchodilators. From late 2006, guidelines discouraging cough medicine use have been widely disseminated and in 2009 national directives to decrease cough medicine use were issued. RESULTS: Across the studies, 17 963 children were eligible. Their median age and length of hospital stay were comparable. The proportion of children who received cough medicines shrank across the surveys: approximately 6% [95% CI: 5.4, 6.6] of children had a prescription in 2015 vs. 40% [95% CI: 35.5, 45.6] in 2002. The most common active ingredients were antihistamines and bronchodilators. The relative proportion that included antihistamines has increased over time. CONCLUSIONS: There has been an overall decline in the use of cough medicines among hospitalised children over time. This decline has been associated with educational, policy and mass media interventions.
[Mh] Termos MeSH primário: Tosse/tratamento farmacológico
Dispneia/tratamento farmacológico
Hospitalização
Prescrição Inadequada
Padrões de Prática Médica
Fármacos do Sistema Respiratório/uso terapêutico
Infecções Respiratórias/tratamento farmacológico
[Mh] Termos MeSH secundário: Antitussígenos/uso terapêutico
Broncodilatadores/uso terapêutico
Pré-Escolar
Estudos Transversais
Prescrições de Medicamentos
Expectorantes/uso terapêutico
Antagonistas dos Receptores Histamínicos/uso terapêutico
Seres Humanos
Lactente
Quênia
Descongestionantes Nasais/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antitussive Agents); 0 (Bronchodilator Agents); 0 (Expectorants); 0 (Histamine Antagonists); 0 (Nasal Decongestants); 0 (Respiratory System Agents)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170705
[Lr] Data última revisão:
170705
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161220
[St] Status:MEDLINE
[do] DOI:10.1111/tmi.12831


  10 / 1541 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27925348
[Au] Autor:Klimek L; Schumacher H; Schütt T; Gräter H; Mueck T; Michel MC
[Ad] Endereço:Center for Rhinology and Allergology, Wiesbaden, Germany.
[Ti] Título:Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms.
[So] Source:Int J Clin Pract;71(2), 2017 Feb.
[Is] ISSN:1742-1241
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: The aim of this study was to explore factors affecting efficacy of treatment of common cold symptoms with an over-the-counter ibuprofen/pseudoephedrine combination product. METHODS: Data from an anonymous survey among 1770 pharmacy customers purchasing the combination product for treatment of own common cold symptoms underwent post-hoc descriptive analysis. Scores of symptoms typically responsive to ibuprofen (headache, pharyngeal pain, joint pain and fever), typically responsive to pseudoephedrine (congested nose, congested sinus and runny nose), considered non-specific (sneezing, fatigue, dry cough, cough with expectoration) and comprising all 11 symptoms were analysed. Multiple regression analysis was applied to explore factors associated with greater reduction in symptom intensity or greater probability of experiencing a symptom reduction of at least 50%. RESULTS: After intake of first dose of medication, typically ibuprofen-sensitive, pseudoephedrine-responsive, non-specific and total symptoms were reduced by 60.0%, 46.3%, 45.4% and 52.8%, respectively. A symptom reduction of at least 50% was reported by 73.6%, 55.1%, 50.9% and 61.6% of participants, respectively. A high baseline score was associated with greater reductions in symptom scores but smaller probability of achieving an improvement of at least 50%. Across both multiple regression approaches, two tablets at first dosing were more effective than one and (except for ibuprofen-sensitive symptoms) starting treatment later than day 2 of the cold was generally less effective. DISCUSSION AND CONCLUSIONS: Efficacy of an ibuprofen/pseudoephedrine combination in the treatment of common cold symptoms was dose-dependent and greatest when treatment started within the first 2 days after onset of symptoms.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Resfriado Comum/tratamento farmacológico
Ibuprofeno/uso terapêutico
Descongestionantes Nasais/uso terapêutico
Pseudoefedrina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Anti-Inflamatórios não Esteroides/administração & dosagem
Esquema de Medicação
Quimioterapia Combinada
Feminino
Seres Humanos
Ibuprofeno/administração & dosagem
Masculino
Descongestionantes Nasais/administração & dosagem
Medicamentos sem Prescrição
Medição da Dor
Pseudoefedrina/administração & dosagem
Inquéritos e Questionários
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Nasal Decongestants); 0 (Nonprescription Drugs); 7CUC9DDI9F (Pseudoephedrine); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161208
[St] Status:MEDLINE
[do] DOI:10.1111/ijcp.12907



página 1 de 155 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde